logo-loader

Silence Therapeutics CEO on potential of pancreatic cancer drug

Published: 15:29 01 Jun 2015 BST

The chief executive of Silence Therapeutics (LON:SLN), Ali Mortazavi, says there is significant commercial opportunity for the company's pancreatic cancer drug, Atu027, following encouraging treatment data.

“Currently there are only four approved drugs in pancreatic cancer,” said the CEO speaking to Proactive.  “They all have very modest improvements in overall survival so there is clear market opportunity for the company in this space.”

Mortazavi’s was speaking after biotech firm unveiled some promising early data that points to the efficacy of its treatment pancreatic cancer sufferers.
 

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

3 hours, 3 minutes ago